Suchergebnisse - "Clinical Trial, Phase III"

PubPharm (20)

1

First line therapy for locally advanced or metastatic urothelial cancer : A randomized double blind phase III multicenter study on adjuvant nivolumab therapy versus placebo in patients with invasive high-risk urothelial cancer (CheckMate 274)-AB 58/17 of the AUO

enthalten in: Der Urologe. Ausg. A | 2017

von Rexer, H. | Ohlmann, C. | Gschwend, J. | +1

2

First-line therapy for locally advanced or metastatic urothelial carcinoma : A randomized, controlled phase III trial comparing pembrolizumab with or without platinum-based combination chemotherapy and chemotherapy only in patients with advanced or metastatic urothelial carcinoma (keynote 361-AB 54/16 of the AUO)

enthalten in: Der Urologe. Ausg. A | 2017

von Rexer, H. | Ohlmann, C. | Retz, M.

3

First-line therapy in advanced renal cell carcinoma : A randomized, open-label phase III study evaluating the efficacy and safety of pembrolizumab (MK-3475) in combination with axitinib compared to sunitinib monotherapy as first-line treatment for locally advanced or metastatic renal cell carcinoma (mRCC) (Keynote-426) - AN 39/16 of the AUO

enthalten in: Der Urologe. Ausg. A | 2017

von Rexer, H. | Bedke, J.

4

Inclusion of oxaliplatin in the multimodal treatment of locally advanced rectal cancer

enthalten in: Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al | 2017

von Rödel, C. | Fokas, E.

5

Association of HPV infection, p16 status, and efficacy of radiotherapy with or without cetuximab in advanced oropharyngeal squamous cell carcinoma

enthalten in: Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al | 2016

von Nieder, C.

6

Adjuvant study of high-risk muscle invasive urothelial carcinoma : Open-label, multicenter, randomized phase III study with atezolizumab (anti-PD-L1 antibody) as adjuvant therapy compared with observation in patients with high-risk muscle invasive urothelial carcinoma after surgical resection (IMvigor010)- study AB 53/15 of the AUO

enthalten in: Der Urologe. Ausg. A | 2016

von Rexer, H. | Retz, M. | Albers, P.

7

Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer : Final Results of the NO16968 Randomized Controlled Phase III Trial

enthalten in: Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al | 2016

von Kubicka, S.

8

Study for the treatment of nonmuscle invasive bladder cancer : A phase III efficacy trial for intravesical instillation of mistletoe extract in superficial bladder cancer (TIM) - AB 40/11 of the AUO

enthalten in: Der Urologe. Ausg. A | 2016

von Rexer, H. | Geschäftsstelle der AUO

9

Therapy monitoring and management of adverse events in PD-1/PD-L1 immune checkpoint inhibition

enthalten in: Der Urologe. Ausg. A | 2016

von Oppel-Heuchel, H. | Grimm, M.

10

A multicentric, randomized, double-blind, placebo-controlled Phase III study of ARN-509 in men with non-metastatic (M0) castration-resistant prostate cancer (SPARTAN) : AUO study AP 82/14

enthalten in: Der Urologe. Ausg. A | 2016

von Rexer, H. | Hammerer, P.